glp-1 business research2guidance GLP-1 Receptor Agonist Market Size,

Weight loss effects of GLP-1RAs Liraglutide (3.0 mg, Saxenda), a GLP-1RA that activates the GLP-1 receptor, was approved by the FDA in December 2014 for adult obesity treatment [38] and has recently shown efficacy in adolescents aged 12 to 18 years

[1] It is not approved for treating type 2 diabetes, though its active ingredient tirzepatide is marketed separately as Mounjaro for that indication

The risk of yo-yo effects, where patients lose muscle on the drug and regain fat after stopping, is a real concern

IV therapy is a wellness treatment that delivers fluids, vitamins, minerals, and nutrients directly into the bloodstream through an intravenous line

phosphorus 120 mg Calcium hydrogen phosphate 474.5 mg equiv

However, in OA, M2 numbers are limited and may shift toward an M1-like phenotype under sustained inflammatory stimuli, reducing their capacity to maintain iron homeostasis (109, 110).Together, these insights support the hypothesis that iron metabolism in M1 macrophages not only contributes to ferroptosis susceptibility in OA, but also represents a potential immunometabolic checkpoint for therapeutic intervention